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protamine sulfate and warfarin), one antiplatelet drug 
(aspirin) and several thrombolytic agents. Heparin and 
warfarin are commonly used clinically for prevention 
and treatment of venous thrombosis and pulmonary 
CROSS-REFERENCE TO RELATED 
APPLICATION 
S embolism. Heparin inhibits the blood coagulation activ-
ity by accelerating the binding of natural plasma prote-
ase inhibitor antithrombin III with coagulation factors, 
and warfarin acts as a vitamin K antagonist and inhibits 
This application is a continuation-in-part of co-pend-
ing application Ser. No. 374,980, filed on July 3, 1989, 
which issued as U.S. Pat. No. 4,954,519 Sept. 4, 1990, 
which in turn was a continuation-in-part of application 10 
Ser. No. 43,647, filed on Apr. 28, 1987, which issued as 
U.S. Pat. No. 4,845,242 on July 4, 1989, which in turn 
was a continuation-in-part of application Ser. No. 
874,459, filed on June 13, 1986, now abandoned, which 
the synthesis of coagulation factors. None of the antico-
agulant drugs, antithrombotic drugs, fibrinolytic agents 
and antiplatelet drugs are highly effective in all clinical 
in turn was a of application Ser. No. 642,995, filed on 
Aug. 20, 1984, which issued as U.S. Pat. No. 4,596,822 
on June 24, 1986. 
BACKGROUND OF THE INVENTION 
situations and many induce side reactions [Von Kaulla, 
Burger's Medicinal Chemistry, Part II. pp. 1081-1132 
(Wolff ed., 1979), incorporated herein by reference]. 
IS Coagulation disorders such as disseminated intravascu-
lar coagulation, bleeding complications of medical and 
surgical procedures and bleeding complications of sys-
temic illness are still difficult to manage [Ingram, Bro-
zovic and Slater, Bleeding Disorders, pp. 1-413 (Black-
1. Field of the Invention 20 well Scientific Publications, 1982), incorporated herein 
This invention relates to a.nave~ cl~~ ?fheter~y~lic by reference]. In the treatment of patients with coagula-
compounds use~ul for .sel~c~1_vely inh1b1tmg t:yp~m-hke tion problems, anticoagulant or antithrombotic agents 
enzymes, sel~ct1vel?' 1~?1tmg chymotrypsm-hke en- of diverse mechanisms are urgently sought in order to 
~yi:ie.s •. select.1vely 1nh1b1tmg elastase or fo.r ~ener~lly 
2
s provide better medical care. 
mh1b1tmg senne proteases of all clas.ses. This mvent1on Anti-inflammatory agents are used to treat elastase-
3;1so relates to a meth~d o_f contro~lmg ~lood coagula- associated inflammation including rheumatoid arthritis 
~ion, .complement act~vat~on, fibf111:olys1s,. an~ tumor and emphysema. Although the naturally occurring pro-
~vas~vene~s ~d tre~tmg 1~flammatmn, bhstenng, and tease inhibitor, al-protease inhibitor (al-Pl) has been 
viral mfectlon m patients usmg the novel compounds of d t t t t' t ·th h th. .nh.b't · 
h · · w h fi h . . 30 use o rea pa 1en s w1 emp ysema, 1s 1 1 1 or 1s t e present mvent1on. e ave ound t at 1socoumanns t ·d 1 d 1. · all d t th hi h d b · d · h b · . h.b. f no w1 e y use c wc y ue o e g osage 
su stltute wit as1c groups are potent m 1 1tors o d d fi th t t t d d'ffi It f d · 
blood coagulation enzymes, tryptases and plasmin, and nee e or. . e rea men an 1 icu Y 0 p:o ucmg 
isocoumarins substituted with hydrophobic groups are larg~ q~a~t1t1es. Therefore small molecular weight elas-
potent inhibitors of chymases and elastases, therefore tase inhibitors are needed for therapy. 
they are useful as anticoagulants, anti-inflammatory and 3S SUMMARY OF THE INVENTION 
anti-tumor agents. 
2. Description of the Related Art 
Serine proteases play critical roles in several physio-
logical processes such as digestion, blood coagulation, 
complement activation, fibrinolysis, viral infection, fer- 40 
tilization, and reproduction. Serine proteases are not 
only a physiological necessity, but also a potential ha-
zard if they are not controlled. Blood coagulation serine 
proteases are responsible for vascular clotting, cerebral 
infarction, and coronary infarction. Plasmin and plas- 45 
minogen activator are involved in tumor invasiveness, 
tissue remodeling, blistering, and clot dissociation. Un-
controlled proteolysis by elastases may cause pancreati-
tis, emphysema, rheumatoid arthritis, bronchial inflam-
mation and adult respiratory distress syndrome. It has 50 
been suggested that a new trypsin-like cellular enzyme 
is involved in the infection of human immunodeficiency 
virus type 1 [HIV-1; Hattori et al., FEBS Letters 248, 
pp. 48-52 (1989)], which is a causative agent of acquired 
immunodeficiency syndrome (AIDS). Accordingly, SS 
specific and selective inhibitors of these proteases 
should be potent anticoagulants, anti-inflammtory 
agents, anti-tumor agents and anti-viral agents useful in 
the treatment of protease-related diseases [Powers and 
Harper, Proteinase Inhibitors. pp. 55-152 (Barrett and 60 
Salvesen, eds., Elsevier, 1986), incorporated herein by 
reference]. In vitro proteolysis by trypsin, chymotryp-
sin or the elastase family is a serious problem in the 
production, purification, isolation, transport or storage 
of peptides and proteins. 6S 
Anticoagulants and antithrombotic drugs are used in 
a variety of thrombotic disorders. The 1986 Physician's 
Desk Reference list three anticoagulant drugs (heparin, 
It is an object of this invention to define a novel group 
of specific inhibitors for trypsin, elastase, chymotrypsin 
and other serine proteases of similar substrate specificity 
and for serine proteases in general. Inhibitors are com-
pounds that reduce or eliminate the catalytic activity of 
the enzyme. Trypsin and trypsin-like enzymes normally 
cleave peptide bonds in proteins and peptides where the 
amino acid residue on the carbonyl side of the split bond 
(P1 residue) is Lys or Arg. Elastase and elastase-like 
enzymes, on the other hand, cleave peptide bonds 
where the P1 amino acid is Ala, Val, Ser, Leu and other 
similar amino acids. Chymotrypsin and chymotrypsin-
like enzymes hydrolyze peptide bonds where P1 amino 
acid is Trp, Tyr, Phe, Met, Leu or other amino acid 
residues which contain aromatic or large alkyl side 
chains. All of the above enzymes have extensive sec-
ondary specificity and recognize amino acid residues 
removed from the P1 residue. 
It is an object of this invention to defme new protease 
inhibitors, especially blood coagulation enzyme inhibi-
tors, which can act as anticoagulants in vitro and in 
vivo. Such inhibitors could be used in prevention of 
thrombosis during periods of stasis and/or endothelial 
damage is segments of vasculature. They could also be 
used in an adjunct to fibrinolytic therapy to prevent 
acute coronary or peripheral artery reclosure. The in-
hibitors of this invention would be useful as the sole 
method of maintaining anticoagulation in extracorpo-
real blood circuits such as the kidney hemodialysis, and 
heart lung bypass. Such inhibitors could also be used as 
alternate anticoagulants when conventional anticoagu-
lation with heparin or coumarin fail or is contraindi-
3 
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cated. The inhibitors of this invention would also be 
useful in the therapy for disseminated intravascular 
coagulation syndromes (DIC). They could also be used 
in prophylaxis against thrombosis in high risk situation 
involving myocardium (e.g. unstable angina). 5 
It is another object of this invention to define new 
protease inhibitors, especially elastase inhibitors, tryp-
tase inhibitors, chymase inhibitors and plasmin inhibi-
tors. These inhibitors are useful for controlling tissue 10 
damage and various inflammatory conditions mediated 
by proteases particularly elastases. The inhibitors of this 
invention would be useful for treating diseases related 
to plasmin; such as tumor invasiveness and blistering. 
The inhibitors of this invention would also be useful for 15 
controlling hormone processing by serine proteases and 
for treating related to tryptases and chymases such as 
inflammation and skin blistering. The inhibitors of this 
invention are useful for treating diseases related to tryp- 2 
tases and caused by viral infection such as AIDS. o 
It is a further object of this invention to define a novel 
group of specific inhibitors useful in vitro for inhibiting 
trypsin, elastase, chymotrypsin and other serine pro-
teases of similar specificity and for inhibiting serine 25 
proteases in general. Such inhibitors could be used to 
identify new proteolytic enzymes encountered in re-
search. They could also be used in research and indus-
trially to prevent undesired proteolysis that occurs dur-
ing the production, isolation, purification, transport and 30 . 
storage of valuable peptides and proteins. Such proteo-
lysis often destroys or alters the activity and/or func-
tion of the peptides and proteins. Uses would include 
the addition of the inhibitors to antibodies, enzymes, 35 
plasma proteins, tissue extracts or other proteins and 
peptides which are widely sold for use in clinical analy-
ses, biomedical research, and for many other reasons. 
For some uses a specific inhibitor would be desirable, 
while in other cases, an inhibitor with general specific- 40 
ity would be preferred. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Isocoumarins with cationic substituents have been 45 
found to be excellent inhibitors of several serine pro-
teases including bovine thrombin, human thrombin, 
human factor Xa, human factor Xia, human factor 
Xlla, bovine trypsin, human plasma plasmin, human 50 
tissue plasminogen activator, human lung tryptase, rat 
skin tryptase, human leukocyte elastase, porcine pancre-
atic elastase, bovine chymotrypsin and human leuko-
cyte cathepsin G. These compounds inhibit the serine 
proteases by reaction with active site serine to form an 55 
acyl enzyme, which in some cases may further react 
with another active site nucleophile to form an addi-
tional covalent bond. These structures may be used in 
vivo to treat diseases resulting from uncontrolled blood 
coagulation or disease caused by uncontrolled proteoly- 60 
sis by elastase, chymotrypsin, trypsin and related serine 
proteases. These inhibitors may be used in vitro to pre-
vent proteolysis which occurs in the process of produc-
tion, isolation, purification, storage and transport of 65 
peptides and proteins. The novel substituted isocouma-
rin and related heterocyclic compounds have the fol-
lowing structural formula: 
0 
RyY~ 
~z 
(I) 
y 
or a pharmaceutically acceptable salt, wherein 
Z is selected from the group consistsing of Ct-6 alk-
oxy with an amino group attached to the alkoxy 
group, Ct-6 alkoxy with an isothiureido group at-
tached to the alkoxy group, Ct-6 alkoxy with a 
guanidino group attached to the alkoxy group, 
Ct-6 alkoxy with an amidino group attached to the 
alkoxy group, Ct-6 alkyl with an amino group at-
tached to the alkyl group, C1-6alkyl with an isothi-
ureido group attached to the alkyl group, C1-6alkyl 
with an guanidino group attached to the alkyl 
group, Ct-6 alkyl with an amidino group attached 
to the alkyl group, 
R is selected from the group consisting of O=C-
N-, S==C=N-, AA-NH-, 
AA-AA-NH-, AA-0-, AA-AA-0-, 
M-NH-, M-AA-NH-, 
M-AA-AA-NH-,M-0-,M-AA-O-, 
M-AA-AA-0-, 
wherein AA represents alanine, valine, leucine, iso-
leucine, proline, methionine, phenylalanine, trypto-
phan, glycine , serine, threonine, cysteine, tyrosine, 
asparagine, glutamine, aspartic acid, glutamic acid, 
lysine, arginine, histidine, beta-alanine, norleucine, 
norvaline, alpha-aminobutyric acid, epsilon-
aminocaproic acid, citrulline, hydroxyproline, or-
nithine or sarcosine, 
wherein M represents NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS-, 
X-NH-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-0-CS-, 
wherein X represents Ct-6 alkyl, Ct-6 fluoroalkyl, 
Ct-6 alkyl substituted with K, Ct-6 fluoroalkyl sub-
stituted with K, phenyl, phenyl substituted with J, 
phenyl disubstituted with J, phenyl trisubstituted 
with J, naphthyl, naphthyl substituted with J, 
naphthyl disubstituted with J, naphthyl trisubstitu-
ted with J, Ct-6 alkyl with an attached phenyl 
group, Ct-6 alkyl with two attached phenyl groups, 
Ct-6 alkyl with an attached phenyl group substi-
tuted with J, or Ct-6 alkyl with two attached 
phenyl groups substituted with J, 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2, Ct-6 alkyl, Ct-6 alkoxy, Ct-6 alkylamine, Ct-6 
dialkylamine, or Ct-6 alkyl-0-CO-, 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, C1-6alkoxy, C1-6alkylamine, C1-6dialk-
ylamine, or Ct-6 alkyl-0-CO-, 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy, 
The compounds of Formula (I) can also contain one 
or more substituents at position B as shown in the fol-
lowing structure: 
5 
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R 
B 
B 
B 
0 
II 
y 
0 
z 
7-(acetylamino )-4-chloro-3-(3-isothiureidopropox-
y )isocoumarin (CH3CONH-CiTPrOIC) 
7-(3-phenylpropionylamino )-4-3-(3-isothiureidopropox-
y)isocoumarin (PhCH2CH2CPNH-CiTPrOIC) 
5 7-(phenylacetylamino )-4-chloro-3-(3-isothiureido-
propoxy )isocoumarin (PhCH2COHNH-CiTPrOIC) 
7-(L-phenylalanylamino )-4-chloro-3-(3-isothiureido-
propoxy )isocoumarin (L-Phe-NH-CiTPrOI C) 
7-(N-t-butyloxycarbonyl-L-phenylalanylamino)-4-
wherein electronegative substituents for position B such 10 chloro-3-(3-isothiureidopropoxy)isocoumarin (Boc-
as N02, CN, Cl, COOR, and COOH will increase the L-Phe-NH-CiTPrOIC) 
reactivity of the isocoumarin, and electropositive sub- 7-(D-phenylalanylamino)-4-chloro-3-(3-isothiureido-
stituents such as NH2, OH, alkoxy, thioalkyl, alkyl, propoxy)isocoumarin (D-Phe-NH-CiTPrOIC) 
alkylamino, and dialkylamino will increase its stability. 7-(N-t-butyloxycarbonyl-D-phenylalanylamino)-4-
Neutral substituents could also increase the stability of 15 chloro-3-(3-isothiureidopropoxy)isocoumarin (Boc-
acyl enzyme and improve the effectiveness of the inhibi- D-Phe-NH-CoTPrOIC) 
tors. 7-(benzylcarbamoylamino)-4-chloro-3-(2-isothiureidoe-
Other substituted isocoumarins have been prepared thoxy)isocoumarin )PhCH2NHCONH-CiTEtOIC) 
earlier for other purposes (illustrative examples: 3- 7(phenylcarbamoylamino)-4-chloro-3-(2-isothiureidoe-
chloroisocoumarin, Davies and Poole, J. Chem Soc., 20 thoxy)isocoumarin (PhNHCONH-CiTEtOIC) 
pp. 1616-1629 (1928); 3-chloro and 3,4- 7(isopropylcarbamoylamino4-chloro-3-(2-isothiureido-
dichloroisocoumarin, Milevskaya, Belinskaya, and ethyxy)isocoumarin ((CH3)2CHNHCONH-
Yagupol'skii, Zhur. Org. Khim. 9, pp. 2145-2149 (1973); CiTEtOIC) 
3-methyl and 4-carboxy-3-methylisocoumarin, Tirod- 7-phenylacetylamino )-4-chloro-3-(2isothiureidoethox-
kar and Usgaonkar, Ind. J. Chem. 7, pp. 1114-1116 25 y)isocoumarin )PhCH2CONH-CiTEtOIC) 
(1969); 7-nitro and 7-aminoisocoumarin, Choksey and 7-(L-phenylalanylamino)-4-chloro-3-(2-isothiureidoe-
Usgaonkar, Ind. J. Chem. 14B, pp. 596-598 (1976), the thoxy)isocoumarin (L-Phe-NH-CiTEtOIC) 
preceding articles are incorporated herein by refer- 7-(N-t-butyloxycarbopyl-L-phenylalanylamino)-4-
ence). chloro-3-(2-isothiureidoethoxy)isocoumarin (Boe-L-
A number of other substituted isocoumarins have 30 · Phe-NH-CiTEtOIC) 
been prepared recently for inhibition of serine proteases 7-(D-phenylalanylamino )-4-chloro-3-(2-isothiureidoe-
(3-chloroisocoumarin, Harper, Hemmi, and Powers, J. thoxy)isocoumarin (D-Phe-NH-CiTEtOIC) 
Am. Chem. Soc. 105, pp. 6518-6520 (1983); 3,4- 7-(N-t-butyloxycarbonyl-D-phenylalanylamino)-4-
dichloroisocoumarin, Harper, Hemmi, and Powers, chloro-3-(2-isothiureidoethoxy)isocoumarin (Boc-D-
Biochemistry 24, pp. 1831-1841 (1985); 3-alkoxy-7- 35 Phe-NH-CiTEtOIC) 
amino-4-chloroisocoumarin, Harper and Powers, J. Am. 7-(N-t-butyloxycarbonyl-L-alanyl-L-alanylamino)-4-
Chem. Soc. 106, pp. 7618-7619 (1984), Harper and Pow- chloro-3-(2-isothiureidoethoxy)isocoumarin (Boc-
ers, Biochemistry 24, 7200-7213 (1983); substituted Ala-Ala-NH-CiTEtOIC) . 
isocoumarins with basic groups (aminoalkoxy, 7-(L-alanyl-L-alanylamino)-4-chloro-3-(2-isothiureido-
guanidino or isothiureidoalkoxy), Kam, Fujikawa and 40 ethoxy)isocoumarin (Ala-Ala-NH-CiTEtOIC) 
Powers, Biochemistry 27, pp. 2547-2557 (1988); 7-sub- 7-(1-naphthylcarbamoylamino)-4-chloro-3-(2-isothi-
stituted 3-alkoxy-4-chloroisocoumarins, Powers, Kam, ureidoethoxy)isocoumarin (NaphthylNH-
Narasimhan, Oleksyszyn, Hernandez and Ueda, J. Cell CiTEtOIC) 
Biochem. 39, pp. 33-46 (1989), Powers, Oleksyszyn, 7-~(S)-c:·m~thylbenzyl_carbamoy~amino)-4-chloro-3-(2-
Narasimhan, Kam, Radhakrishnan and Meyer, Jr. Bio- 45 1soth1ure1doethoxy)1socoumann (S-
chemistry 29, pp. 3108-3118 (1990), the preceding arti- C61is(CH3)CHNHCONH-CiTEt?IC) 
cles are incorporated herein by reference· Powers and 7-((R)-a-methylbenzylcarbamoylammo)-4-chloro-3-(2-
Harper, U.S. Pat. No. 4,596,822; Powers a~d Kam, U.S. isothiureidoethoxy)isocoumarin (R-
Pat. No. 4,845,242 which are also incorporated by refer- C61is(CH3)CHNHCONH-CiTEtOIC) 
ence). 50 7-dansylamino-4-chloro-3-(2-isothiureidoethox-
The following compounds are representative of but y)isocou~arin (Dansyll'_l"H-CiTEtOIC) . . 
do not limit the invention: 7-phenylthiocarbamoylammo-4-chloro-3-(2-1sothi-
CiTEtOIC (n=2); CiTPrOIC (n=3) 
7-(benzylcarbamoylamino)-4-chloro-3-(3-isothiureido-
ureidoethoxy)isocoumarin (PhNHCSNH-
CiTEtOIC) 
55 7-(m-carboxyphenylthiocarbamoyl)amino-4-chloro-3-
(2-isothiureidoethoxy )isocoumarin (m-COOH-
PhNHCSNH-CiTEtOl C) 
7-(p-carboxyphenhylthiocarbamoyl)amino-4-chloro-3-
(2-isothiurcidoethoxy )isocoumarin (p-COOH-
60 PhNHCSNH-CiTEtOIC) 
propoxy)isocoumarin (PhCH2NHCONH-CiT- 65 
It has been found that compounds of Formula (I) 
have anticoagulant activity as shown in Table I by ef-
fective inhibition of the proteolytic function of blood 
coagulation enzymes in Hepes buffer. Compounds of 
Formula (I) also have anticoagulant effect in vitro as 
shown in Table IV by prolongation of the prothrombin PrOIC) 
7-(phenylcarbamoylamino )-4-chloro-3-(3-isothiureido-
propoxy )isocoumarin (PhNHCONH-CiTPrOIC) 
time (PT) and activated partial thromboplastin time 
(APTT) in pig plasma. Compounds of Formula (I) are 
7 
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effective in the detection, prevention and inhibition of factor Xa and human factor Xia. The isocoumarin with 
adult and infantile respiratory distress syndrome (a con- R group of L-Phe, Y group of Cl and Z group of isothi-
sequence of acute lung injuries) as shown in Table II by ureidoethoxy is the best inhibitor for human factor 
the effective inhibition of the proteolytic function of XIIa. 
human lung tryptase. Sheep lung lymph tryptase is 5 Table II shows the inactivation of human lung tryp-
utilized as a marker of Jung capillary injury, and this is tase, human skin tryptase and rat skin tryptase by substi-
shown in the articles by Lesser et al., Am. Rev. Respir. tuted isocoumarins. The structures with R groups of 
Dis. 135, pp. 643-650 (1987) and by Orlowski et al., substituted amino, Y group of Cl, and Z group of isothi-
Arch.Biochem. Biophys. 269, pp. 125-136 (1989), which ureidoalkoxy are good inhibitors for all three tryptases. 
are incorporated herein by reference. Compounds of 10 Table II also shows the inactivation rate constants for 
Formula (I) are effective in treating a variety of blister- human plasmin and human tissue plasminogen activator 
ing diseases as shown in Table II by the effective inhibi- by these substituted isocoumarins. The structure with R 
tion of proteolytic function of rat skin tryptase and groups of substituted amino, Y groups of Cl, and Z 
human skin tryptase. It has been found that compounds group of isothiureidoalkoxy inhibited both enzymes 
of Formula (I) have anti-tumor activity as shown in 15 potently. Table III shows the inactivation rate constants 
Table II by the effective inhibition of the proteolytic of porcine pancreatic elastase (PPE), human leukocyte 
function of human plasma plasmin and human tissue elastase (HLE), chymotrypsin and cathepsin G inhib-
plasminogen activator. Compounds of Formula (I) have ited by substituted isocoumarins. Although the inactiva-
anti-inflammatory activity and are effective in the treat- tion by these inhibitors was less efficient toward PPE 
ment of pulmonary emphysema and adult respiratory 20 and cathepsin G than trypsin-like enzymes, the struc-
distress syndrome as shown in Table III by the effective ture with R group of phenylcarbamoylamino, Y group 
inhibition of the proteolytic function of human leuko- of Cl, and Z group of isothiureidoethoxy is a potent 
cyte elastase. inhibitor of HLE. The structure with R group of 
In activation rates of serine proteases by substituted phenylacetylamino, Y group of Cl, and Z-group of 
isocoumarins were measured by the incubation method. 25 isothiureidopropoxy is best at inhibiting chymotrypsin. 
An aliquot of inhibitor (25 or 50 µl) in Me2SO was The spontaneous hydrolysis rate of these substituted 
added to a buffered enzyme solution (0.01-2.3 µM) to isocoumarins in Hepes buffer have been measured and 
initiate the inactivation. Aliquots (50 µI) wen~ with- are summarized in Table V. The isocoumarins substi-
drawn at various intervals and the residual enzymatic tqted with phenylcarbamoylamino or benzylcar-
activity was measured. Me2SO concentration in the 30 bamoylamino at the 7-position are more stable than 
reaction mixture was 8-12% (v/v). 0.1 Hepes, 0.0lM 7-amino-4-chloro-3-(3-isothiureidopropoxy)isocouma-
CaC12, pH 7.5 buffer was utilized for trypsin and coagu- rin. The isocoumarins substituted with 7-alkanoylamino 
lation enzymes. 0.lM Hepes, 0.5M NaCl, pH 7.5 was group are less stable than the parent 7-amino com-
utilized for other serine proteases. The inhibitor con- pound. 
centrations are shown in the Tables I, II, Ill, and IV. 35 Table IV shows the anticoagulant effect of substi-
Peptide thioesters or peptide nitroanilides with appro- tuted isocoumarins in pig plasma. The prothrombin time 
priate sequence were used as substrates for various (PT) and activated partial thromboplastin time (APTT) 
serine proteases. All peptide thioester hydrolysis rates were measured in the presence of various inhibitors. 
were measured with assay mixtures containing 4,4' - 7 -(Phenylcarbamoylamino )-4-chloro-3-(2-isothiureido-
dithiodipyridine (E324=19800 M-lcm- 1; Grasetti & 40 ethoxy)isocoumarin prolong PT 3.1 fold at 32 µM, and 
Murray, Arch. Biochem. Biophys. 119, pp. 41-49 (1967), it also prolongs APTT more than 6.8 fold at 16 µM. 
incorporated herein by reference). Peptide 4-nitroani- 7-(Benmzylcarbamoylamino)-. or 7-(a-methylbenzyl-
Iide hydrolysis was measured at 410 nm (e410=8800 carbamoylamino)-3-(2-isothiureidoethoxy)-4-
M-lcm-1; Erlanger et al., Arch. Biochem. Biophys. 95, chloroisocoumarin prolongs APTT more than 6.8 fold 
pp. 271-278 (1961), incorporated herein by reference). 45 and increases PT 1.5 fold at 32 µM. 
First order inactivation rate constants Ckobs) were ob- Anticoagulants can prolong the clotting time of 
tained from plots in ln (vr/v0) vs time, and the correla- human plasma and play important roles in the treatment 
tion coefficients were greater than 0.98. of blood coagulation related diseases such as vascular 
When the isocoumarin structure contains a basic clotting, cerebral infarction and coronary infarction 
functional group such as isothiureidoalkoxy as Z, substi- so [Williams et al. Hematology, 3rd ed. (McGraw Hill, 
tuted amino as Rand Cl as Y, the compound is gener- 1983) and Ingram et al. Bleeding Disorders, 2nd ed. 
ally a good inhibitor for trypsin, blood coagulation (Blackwell Scientific Publications, 1985). These two 
enzymes and other tryptases. The inactivation of the books are incorporated herein by reference]. The pres-
enzyme is time dependent, and the kobsl[I] values are ence of certain inhibitors of this invention in pig plasma 
second order rate contstants. In most cases, inactivation SS prolong the prothrombin time and activated partial 
of the enzyme occurs at the inhibitor concentration of thromboplastin time quite effectively, therefore these 
5-400 times the enzyme concentration and the first compounds act as anticoagulants in vitro. Currently, 
order rate constant kobs is obtained. The inactivation there are few anticoagulant and antithrombotic drugs in 
rate of the enzyme depends on the substituents R, Y and use clinically, and the inhibitors described in this inven-
z. Table I shows the inactivation rate constants for 60 tion can be used as anticoagulants or antithrombotics in 
trypsin and blood coagulation enzymes inhibited by mammals (including man). 
substituted isocoumarins. The isocoumarins with R Considerable evidence has been shown that plasmino-
groups of phenylcarbamoylamino or S-methylbenzyl- gen activator, leukocyte elastase and/or related en-
carbamoylamino, Y group of Cl and Z group of isothi- zymes play a role in tumor cell metastasis [Salo, et al., 
ureidoethoxy are the best inhibitors toward bovine and 6S Int. J. Cancer 30, pp. 669-673 (1973); Kao et al., Bio-
human thrombin. The isocoumarin with R group of chem. Biophys. Res. Comm. 105, pp. 383-389 (1982); 
phenylcarbamoylamino, Y group of Cl and Z group of Powers, J. C. Modification of Proteins, R. e. Feeney and 
isothiureidoethoxy is the potent inhibitor for human J. R. Whitaker, eds., Adv. Chem. Ser. 198, pp. 347-367 
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(Amer. Chem. Soc., Wash., D.C. 1982)], therefore it is 
suggested that compounds of this invention may have 
anti-tumor activity. 
Pulmonary emphysema is a disease characterized by 
progressive loss of lung elasticity die to the destruction 5 
of lung elastin and alveoli. The destructive changes of 
lung parentchyma associated with pulmonary emphy-
sema are caused by uncontrolled proteolysis in lung 
tissues (Janoff, Chest 83 pp. 54-58 (1983), incorporated 
herein by reference). A number of proteases have been JO 
shown to induce emphysema in animals [Marco et al., 
Am Rev. Respir. Dis. 104, pp. 595-598 (1971); Kaplan, J. 
Lab. C/in. Med. 82, pp. 349-356 (1973), these two arti-
cles are incorporated herein by reference], particularly 
human leukocyte elastase [Janoff, ibid 115, pp. 461-478 15 
(1977), incorporated herein by reference]. Leukocyte 
elastase and other mediators of inflammation also ap-
pear to play a role in diseases such as mucocutaneous 
lymph node syndrome [Reiger et al., Eur. J. Pediatr. 
140, pp. 92-97 (1983), incorporated herein by reference] 20 
and adult respiratory distress syndrome [Stockley, Clin-
ical Science b 64, pp. 119-126 (1983); Lee et al., N. Eng. 
J. Med. 304, pp. 192-196 (1981); Rinaldo, ibid 301, 
900.:.909 (1982), all these articles are incorporated herein 
by reference]. 25 
It is known that in vitro activity of elastase inhibitors 
correlates with in vivo activity in animal models of 
emphysema and inflammation (Otterness et al., editors, 
Advances in Inflammation Research, Vol. 11, (Raven 
Press 1986), and this article is incorporated herein by 30 
reference). Prophylactic administration of an inhibitor 
of elastase significantly diminishes the extent of elastase-
induced emphysema [Kleinerman et al., Am. Rev. Re-
spir. Dis. 121, pp. 381-387 (1980); Lucey et al., Eur. 
Respir. J. 2, pp. 421-427 (1989)]. Thus the novel inhibi- 35 
tors described here should be useful for the treatment of 
emphysema and inflammation. Elastase inhibitors have 
been used orally, by injection or by instillation in the 
lungs in animal studies (Powers, Am Rev. Respir. Dis., 
127, s54-s58 (1983); Powers and Bengali, Am. Rev. Re- 40 
spir. Dis. 134, pp. 1097-1100 (1986) and these two arti-
cles are incorporated herein by reference). The inhibi-
able salts will normally be in the dosage range from 0.2 
to 140 mg/kg of body weight. Administration is made 
by intravenous, intramuscular or subcutaneous injec-
tion. Accordingly, pharmaceutical compositions for 
parenteral administration will contain in a single dosage 
form about 10 mg to 7 gms of compounds of Formula 
(I) per dose. In addition to the active ingredient, these 
pharmaceutical composition will usually contain a 
buffer, e.g. a phosphate buffer which keeps the pH in 
the range from 3.5 to 7 and also sodium chloride, manni-
tol or sorbitol for adjusting the isotonic pressure. 
A composition for topical application can be formu-
lated as an aqueous solution, lotion, jelly or an oily 
solution or suspension. A composition in the form of an 
aqueous solution is obtained by dissolving the com-
pounds of Formula (I) or their pharmaceutically accept-
able salts in aqueous buffer solution of pH 4 to 6.5 and 
if desired, adding a polymeric binder. An oily formula-
tion for topical application is obtained by suspending 
the compound of Formula (I) or their pharmaceutically 
acceptable salts in a oil, optionally with the addition of 
a swelling agent such as aluminium stearate and/or a 
surfactant. 
To use the above inhibitors in vitro, they are dis-
solved in an organic solvent such as dimethylsulfoxide 
or ethanol, and are added to an aqueous solution con-
taining serine proteases. The final concentration of the 
organic solvent should be less than 25%. The inhibitors 
may also be added as solids or in suspensions. The serine 
protease inhibitors of this invention would be useful in a 
variety of experimental procedures where proteolysis is 
a significant problem. Inclusion of these inhibitors in a 
radioimmunoassay experiments would result in higher 
sensitivity. The use of these inhibitors in plasma frac-
tionation procedures would result in higher yields of 
valuable plasma and would make purification of the 
proteins easier. The inhibitors disclosed here could be 
used in cloning experiments utilizing bacterial cultures, 
yeast and purified cloned product in higher yield. 
The following examples are given to illustrate the 
invention and are not intended to limit it in any manner. 
tors described above can be used by any of these routes. EXAMPLE 1 
For treatment of blood coagulation-related diseases, Preparation of 
tumor invasiveness, viral infection or inflammation, the 45 7-(phenylcarbamoylamino)-4-chloro-3-(2-isothiureidoe-
compounds of Formula (I) or pharmaceutically accept- thoxy)isocoumarin 
able salts may be administered orally, topically or par-
enterally. The term parenteral as used includes subcuta- 7-Amino-3-(2-bromoethoxy)-4-chloroisocoumarin 
neous injection, intravenous, intramuscular, injection or was synthesized as previously described (Powers et al., 
infusion techniques. The dosage depends primarily on 50 Biochemistry 29, pp. 3108-3118 (1990), incorporated 
the specific formulation and on the object of the therapy herein by reference). This compound (0.32 g, 1 mmole) 
or prophylaxis. The amount of the individual doses as was mixed with phenyl isocyanate (0.12 g, 1 mmole) in 
well as the administration is best determined by individ- 5 91 ml of THF and the reaction mixture was stirred at 
ually assessing the particular case. room temperature overnight. The product 7-(phenyl-
The pharmaceutical compositions containing the ac- 55 carbamoylamino)-4-chloro-3-(2-bromoethox-
tive ingredient may be in a form suitable for oral use, for y)isocoumarin precipitated out, yield 40%, melting 
example as tablets, troches. lozenges, aqueous or oily point (m.p.) 215°-217° C., mass spectrum m/e 
suspensions, dispersible powders or granules, emulsions, =437.9(M+). Anal. Cale. for 
hard or soft capsules or syrups or elixirs. Dosage levels C1sH1o4N204ClBr:C,49.40; H, 3.22; N, 6.40; Cl, 8.10. 
of the order to 0.2 mg to 140 mg per kilogram of body 60 Found: C,49.48; H, 3.25; N,6.34; Cl, 8.12. The phenyl-
weight per day are useful in the treatment of above- carbamoylamino compound (0.1 g, 0.23 mmole) was 
indicated conditions (10 mg to 7 gms per patient per heated with 0.02 g ofthiourea (0.26 mmole) in 10 ml of 
day). The amount of active ingredient that may be com- THF at 70° C. overnight. The final product precipitated 
bined with carrier materials to produce a single dosage out, yield 0.04 g, 36%, m.p. 161°-163° C. (dee.), mass 
form will vary depending upon the host treated and the 65 spectrum (FAB+)m/e=433(M-Br). Anal. Cale. for 
particular mode of administration. C19H1sN404ClBrS·0.25 THF: C, 45.12; H, 3.86; N, 
For injection, the therapeutic amount of the com- 10.53; Cl, 6.67. Found: C, 44.83; H, 3.92; N, 10.12; Cl, 
pounds of Formula (I) or their pharmaceutically accept- 6.41. 
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7-(Ethylcarbamoylamino )-4-chloro-3-(2-isothiureido-
ethoxy )isocoumarin, 7-(t-butylcarbamoylamino)-4-
chloro-3-(2-isothiureidoethoxy)isocoumarin, 114 7-
(benzylthiocarbamoylamino)-4-chloro-3-(2-isothi-
ureidoethoxy)isocoumarin, 7-(ethylthiocar- 5 
bamoylamino )-4-chloro-3-(2isothiureidoethox-
y)isocoumarin, 7-(4-fluorobenzyl)thiocarbamoylamino-
4-chloro-3-(2-isothiureidoethoxy)isocoumarin, and 7-
(2,5-dimethylbenzyl)thiocarbamoylamino-4-chloro-3-
(2-isothiureidoethoxy)isocoumarin can be prepared by IO 
using the appropriate isocyanate or isothiocyanate. 
EXAMPLE2 
12 
bromoethoxy)isocoumarin 142 was crystallized from 
THF and Petroleum ether (yield, 73%), m.p. 165°-169° 
C.; mass spectrum; m/e=436.7(M+). The 
phenylacetyamino derivative (0.1 g) was heated with 
thiourea (0.02 g) to give the product 0.05 g (yield, 40% ), 
m.p. 115°-120° C.; mass spectrum FAB+) 
m/e=432(M+-Br). Anal. Cale. for 
C2oH19N304ClBrS·0.5 H20: C 45.99; H, 3.83; N, 8.05; 
Cl, 6.80. Found: C, 46.09; H, 4.17; N, 8.02; Cl, 6.79. 
EXAMPLES 
Preparation of 
Preparation of 7-(R-a-methylbenzylcarbamoylamino)-4-chloro-3-(2-
7-(acetylamino )-4-chloro-3-(3-isothiureidopropox- 15 
y )isocoumarin isothiureidoethoxy )isocoumarin 
7 Amino-3-(3-bromopropoxy )-4-chloroisocoumarin 7-R-a-methylbenzylcarbamoylamino )-4-chloro-3-(2-
was synthesized as previously described (Kam et al., bromoethoxy)isocoumarin was synthesized in the same 
1988). This compound (0.33 g, 1 mmole) was heated manner as described above, m.p. 183°-185° C.; mass 
with 0.15 g of acetic anhydride (1.5 mmole) in 20 ml of 20 spectrum m/e=464 (M+). This compound (0.1 g) re-
dry THF. After a few minutes, a yellow solid precipi- acted with thiourea (0.02 g) under the same condition 
tated out. After 3 ~rs, the solution was. concentrated to described above to form the final product 7-(R-a-
5 ml, and. the solid was filtered to give 0:37 g of 7- methylbenzylcarbamoylamino)-4-chloro-3-(2-isothi-
(acetylammo)-4-chloro-3-(3-bromopropoxy)1socouma- 'd th )' · (O 078 ) 143° 150" c rin, m.p. 170°-172° C.; mass spectrum: m/e=375(m+). 25 urei oe oxy isocoumann · g 'm.p. 30 - .; The acetylated isocoumarin (0.15 g, 0.4 mmole) was mass spectrum FAB)+) m/e=461 (M -Br). Anal. 
treated with thiourea (0.036 g, 0.47 mmole) to give 0.9 Cale. for C21H22N404ClBrS·0.5H20: _C, 45.75; H, 4.35; 
g of the fmal product, (yield 50%), m.p. 180°-181° C., N, 10.17; Cl, 6.44. Found: C, 44.95; H, 4.31; N, 10.02; Cl, 
mass spectrum m/e=370 (M+-Br). Anal. Cale. for C15 6.36. 
H17N304CIBrS: C, 39.97; H, 3.80; N, 9.32; Cl 7.87. 30 
Found: C, 39.86; H 3.83; N, 9.29; Cl, 7.85. 
7-Trifluoroacetylamino-4-chloro-3-(3-isothiureido-
propoxy )isocoumarin, 7-heptafluorobutyroylamino-4-
chloro-3-(3-isothiureidopropoxy)isocoumarin, 7-suc-
cinylamino-4-chloro-3-(3-isothiureidopropox- 35 
y)isocoumarin, and 7-(o-phthalyl)amino-4-chloro-3-(3-
isothiureidopropoxy)isocoumarin can be prepared by 
using the appropriate anhydride. 
EXAMPLE6 
Preparation of 
7-(D-phenylalanylamino )-4-chloro-3-(2-isothiureidoe-
thoxy )isocoumarin 
EXAMPLE3 
Boc-D-Phe (0.33 g, 1.2 mmole) reacted with 1,3-dicy-
clohexylcarbodiimide (0.13 g, 0.6 mmole) in 10 ml THF 
at o· c. for 1 hr to form the symmetric anhydride, and 
then 7-amino-4-chloro-3-(2-bromoethoxy)isocoumarin 40 (0.2 171 g, 0.6 mmole) was added. The reaction was 
Preparation of stirred at room temperature overnight and the precipi-
7-(benzylcarbamoylamino )-4-chloro-3-(3-isothiureido- tate 7-(Boc-D-Phe-amino )-4-chloro-3-(2-bromeothox-propoxy )isocoumarin y)isocoumarin was formed (0.29 g, 71%). Thin layer 
7-(benzylcarbamoylamino)-4-chloro-3-(3-bromo- 45 chromatography (TLC) one spot, m.p. 180•-182• C.; 
propoxy)isocoumarin was prepared from the reaction mass spectrum m/e=566 (M+). Anal Cale. for 
of benzyl isocyanante with 7-amino-4-chloro-3-(3-
bromopropoxy)isocoumarin as described above, m.p. C2sH26N206ClBr: C, 53.07; H, 4.63; N, 4.95; Cl 6.27. 
188°-189° c., mass spectrum: m/e=359(M+-benzyl). Found: C, 53.25; H 4.66; N, 4.87; Cl, 6.24. B~-D-P?e 
The fmal product was obtained from the reaction of compound (0.2 g, 0.35 mmole)was reacted with thio-
7-(benzylcarbamoylamino)-4-chloro-3-(3-bromo- 50 urea (0.027 g, 0.35 mmole) in the same manner to give 
propoxy)isocoumarin with thiourea as described above 7-(Boc-D-phenylalanylamino)-4-chloro-3-(2-isothi-
(yield 74%). m.p. 165°-166° C.; mass spectrum (FAB+) ureidoethoxy)isocoumarin (0.14 g), yield 62%, mass 
m/e=461(M+-Br). Anal Cale. for spectrum (FAB+) m/e 561 (M+-Br). This compound 
C21H22N404ClBrS·0.75 THF: C, 48.36; H, 4.70; N, 9.40; 55 was dissolved in 3 ml of THF at o• C. and then the Cl, 6.56. Found; C, 48.13; H, 4.87; N, 9.65; Cl,6.15. 
EXAMPLE4 
solvent was evaporated to dryness. The fmal product 
precipitated out after addition of ether, one spot on 
TLC (CH3CN:H20:Ac0H=8:1:1); mass spectrum 
(FAB+) m/e 462 (M+-Br-CF3COO). Preparation of 7-(phenylacetylamino )-4-chloro-3--
-(2-isothiureidoethoxy)isocoumarin 60 7-Boc-alanylamino-4-chloro-3-(2isothiureidoethox-
7-Amino-4-chloro-3-(2-bromoethoxy )isocoumarin 
(0.15 g, 0.47 mmole) was first mixed with phenylacetyl 
chloride (0.09 g, 0.55 mmole) in 10 ml ofTHF, triethyl-
amine (0.05 g, 0.47 mmole) was then added and the 65 
reaction mixture was stirred at room temperature over-
night. After Et3N.HCl salt was removed by filtration, 
the product 7-(phenylacetylamino)-4-chloro-3-(2-
y)isocoumarin, 7-bcnzoyl-alanyllamino-4-chloro-3-
(21sothiureidoethoxy)isocourmarin, 7-bcnzoyl-
phenylalanylamino-4-chloro-3-(2-isothiureidoethox-
y)isocoumarin and 7-Boc-valyamino-4-chloro-3-(2-iso-
thiureidocthoxy)isocoumarin can be prepared by using 
appropriate Boe-amino acid or benzoyl-amino acid de-
rivative. 
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EXAMPLE 7 
14 
reaction of m-carboxyphenyl isothiocyanate with 7-
amino-4-chloro-3-(2-bromeothoxy)isocoumarin, yield 
64%, m.p. 157°-158° C.; mass spectrum m/e 361 (M+-
(COOH)PhNH+ 1). Anal. Cale.: C, 45.85; H, 2.84. 
Preparation of 
7-(Boc-alanylalanylamino)-4-chloro-3-(2-isothiureidoe-
thoxy )isocoumarin 5 Found: C, 45.73; H, 2.86. The bromoethoxy compound 
was then reacted with thiourea to give the product, 
yield 21%; mass spectrum (FAB+) m/e/ 493 (M+-Br). 7-Boc-alanylalanylamino)-4-chloro-3-(2-bromeothox-y)isocoumarin was synthesized in the same manner, 
m.p. 147°-151' C.; mass spectrum m/e=56l (M+). 
Anal. Cale.: C, 47.12; H, 4.85. Found: C, 4.87. This 
compound (0.2 g) was reacted with thiourea (0.03 g) by lO 
the same procedure to form 7-(Boc-alanylalanylamino)-
4-chloro-3-(2-isothiureidoethoxy)isocoumarin (0.04 g), 
mass spectrum m/e=556 (M+-Br). 
7-Alanylalanylamino-4-chloro-3-(2-isothiureidoe-
thoxy)isocoumarin was prepared by deblocking of Boe- 15 
Ala-Ala-NH-CiTEtOIC with trifluoracetic acid, mass 
spectrum (FAB+) m/e456 (M+-Br-CF3COO). 
EXAMPLES 
7-(3-Fluorobenzoyl)amino-4-chloro-3-(2-isothi-
ureidoethoxy )isocoumarin, 7-(3-nitrobenzoyl)amino-4-
chloro-3-(2isothiureidoethoxy )isocoumarin, 7-(3-
phenylpropionyl)amino-4-chloro-3-(2-isothiureidoe-
thoxy)isocoumarin, 7-diphenylacetylamino-4-chloro-3-
(2-isothiureidoethoxy)isocoumarin, 7-diphenylpro-
pionylamino-4-chloro-3-(2-isothiureidoethox-
y)isocoumarin, 7-(p-toluenesulfonyl)amino-4-chloro-3-
(2-isothiureidoethoxy)isocoumarin, and 7-(a-
toluenesulfonyl)amino-4-chloro-3-(2-isothiureidoethox-
y)isocoumarin can be prepared from the reaction of 
corresponding 7-substituted-4-chloro-3-(2-bromoethox-
Preparation of 
7-(phenylthiocarbamoylamino )-4-chloro-3-(2-isothi-
ureidoethoxy )isocoumarin 
20 y)isocoumarin with thiourea as described above. 7-sub-
stituted-4-4chloro-3-(2-bromeothoxy)isocoumarin can 
be synthesized by reacting 7-amino-4-chloro-3-(2-
bromeothoxy)isocoumarin with appropriate acid chlo-
7-(Phenylthiocarbamoylamino )-4-chloro-3-(2-bromo-
ethoxy )isocoumarin was prepared from the reaction of 25 
phenyl isothiocyanate with 7-amino-4-chloro-3-(2-
bromoethoxy)isocoumarin, yield 59%, m.p. 157°-158° 
C.; mass spectrum m/e 361 (m+-PhNH+ 1). Anal. 
Cale.: C, 48.36; H, 3.39. Found: C, 48.26; H, 3.40. The 
bromoethoxy compound was then reacted ·with thio- 30 
urea by the same procedure to give the final product, 
yield 32%, mass spectrum (FAB+) m/e 449 (M+-Br). 
EXAMPLE9 
ride or sulfonyl chloride in the presence of Et3N. 
7-Ethoxycarbonylamino-4-chloro-3-(2-isothiureidoe-
thoxy)isocoumarin, 7-benzyloxycarbonylamino-
4chloro-3-(2-isothiureidoethoxy)isocoumarin, and 7-
phenoxycarbonylamino-4-chloro-3-(2-isothiureidoe-
thoxy)isocoumarin can be prepared from the reaction of 
7-substituted-4-chloro-260 3-(2-bromeothox-
y)isocoumarin with thiourea. 7-Ethoxycarbonylamino-
4-chloro-3-(2-bromoethoxy)isocoumarin, 7-benzylox-
ycarbonylamino-4-chloro-3-(2-bromeothoxy)isocouma-
rin and 7-phenoxycarbonylamino-4-chloro-3-(2-
Preparation of 
7-(m-carboxyphenylthiocarbamoylamino )-4-chloro-3-
(2-isothiureidoethoxy )isocoumarin 
35 bromeothoxy)isocoumarin can be synthesized by react-
ing 7-amino-4-chloro-3-(2-bromeothoxy )isocoumarin 
with the corresponding chloroformate. 
7-(m-Carboxyphenylthiocarbamoylamino )-4-chloro-
3-(2-bromoethoxy )isocoumarin was prepared from the 
TABLE 1 
Inhibition Rates of Bovine Trypsin and Coagulation Enzymes by 
7-Substituted-4-chloro-3-isothiureidoalkoxyisocoumarins0 • 
Bovine Bovine Human Human Human Human 
Compounds Trypsinb Thrombin< Thrombind Factor Xa' Factor Xlaf Factor Xllag 
NH2-CiTPrOIC 410,oooh 63oh 7flJ 22,oooh 6,20oh 
PhCH2NHCONH-CiTPrOIC Sl,000 420 700 
PhNHCONH-CiTPrOIC 63,000 970 1,840 so 7,720 
CH3CONH-CiTPrOIC 107,000 420 310 
PhCH2CH2CONH-CiTPrOIC 87,900 820 630 
PhCH2CONH-CiTPrOIC 165,000 600 610 
L-Phe-NH-CiTPrOIC 400 470 
Boc-L-Phe-NH-CiTPrOIC 330 520 
D-Phe-NH-CiTPrOIC 68,300 180 220 
Boc-D-Phe-NH-CiTPrOIC 105,000 190 230 
Ph-NH-CO-NH-CiTEtOIC 21,000 25,000 22,400 4,740 104,000 S0,000 
PhCH2NHCONH-CiTEtOIC 16,800 ll,68P 2,340 105,000 45,000 
PhCH2CONH-CiTEtOIC 15,800 6,730 3,630 59,000 
D-Phe-NH-CiTEtOIC 4,240 3,070 3,070 82,000 
Boc-D-Phe-NH-CiTEtOIC 1,040 1,090 
L-Phe-NH-CiTEtOIC 1,280 1,340 3,770 107,000 
Boc-L-Phe-NH-CiTEtOIC 1,090 1,140 1,620 
Ala-Ala-NH-CiTEtOIC 1,070 880 1,490 
Boc-Ala-Ala-NH-CiTEtOIC 1,530 970 
(CH3)2CHNHCONH-CiTEtOIC 4,100 S,000 
Naphthyl-NHCONH-CiTEtOIC 17,SOO S,800 
S-C6ffs(CH3)CHNHCONH-CiTEtOIC 41,300 21,000 
R·C6ffs(CH3)CHNHCONH-CiTEtOIC 29,SOO 12,000 
PhNHCSNH-CiTEtOIC 21,400 
15 
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TABLE I-continued 
Inhibition Rates of Bovine Trypsin and Coagulation Enzymes by 
7-Substituted-4-chloro-3-isothiureidoalkoxyisocoumarins•. 
16 
Bovine Bovine Human Human Human Human 
Compounds Trypsinb Thrombinc Thrombind Factor Xa' Factor Xlaf Factor Xlla8 
m-Carboxy-PhNHCSNH-CiTEtOIC 17,500 
"Inhibition rates were measured in O.lM Hepes, 0.0lM CaCl2. pH 7.5 buffer, 8% Me2SO and at 25" C. 
binhibitor concentration were 1.1-4.6 µM. 
C'Jnhibitor concentration were 1.2-54 µM. 
dlnhibitor concentration were 1.2-54 µM. 
'Inhibitor concentration were 3.6-44 µM. 
ltnhibitor concentration were 0.7-0.8 µM. 
'Inhibitor concentration were 3.6--4.9 µM. 
"Data was obtained from Kam, Fujikawa, and Powers, Biochemistry 27, pp. 2547-2557 (1988). 
TABLE II 
Inhibition of Several T!:l'.Etases b;t 7-Substituted-4-chloro-3-isothiureidoalkox:t!socoumarins0 • 
~bJ[IJ {M-ls-1~ 
Human Skin Rat Skin Human Lung Human Human 
Compounds Tryptaseh Tryptase< Tryptased Plasmin• r-t-PAf 
NH2-CiTPrOIC 39,000 13,000 
PhCH2NHCONH-CiTPrOIC 68%8 270,000 190,000 5,120 18,000 
PhNHCONH-CiTPrOIC 38,000 250,000 140,000 19,000 
CH3CONH-CiTPrOIC 99,000 60%8 7,000 
PhCH2CH2CONH-CiTPrOIC 170,000 180,000 15,000 
PhCH2CONH-CiTPrOIC 145,000 140,000 9,000 
L-Phe-NH-CiTPrOIC 96,000 54%8 11,000 
Boc-L-Phe-NH-CiTPrOIC 150,000 170,000 6,000 
PhNHCONH-CiTEtOIC 170,000 110,000 32,000 16,000 
PhCH2NHCONH-CiTEtOIC 200,000 280,000 19,000 
PhCH2CONH-CiTEtOIC 120,000 110,000 64%8 
D-Phe-NH-CiTEtOIC 62,000 360,000 60,000 15,000 
Boc-D-Phe-NH-CiTEtOIC 135,000 65%8 
L-Phe-NH-CiTEtOIC 650,000 260,000 13,000 
S-C6ff5(CH3)CHNHCONH-CiTEtOIC 27,800 
"Inhibition rates were measured in O.lM Hepes, O.OlM CaCl2. pH 7.5 buffer for human plasmin; 25 mM Phosphate, 0.5M NaCl, 1 mM 
EDTA, pH 7.5 buffer for rat skin tryptase and O.lM Hepes, 0.5M NaCl, pH 7.5 for human Jung tryptase, human skin tryptase and 
r+PA. All enzymes were assayed with Z-Arg-SBzl (0.07 mM) in the presence of 4,4'-dithiodipyridine (0.33 mM). Reaction mixtures 
contained 8% Me2SO and assays were performed at 25' C. 
htnhibitor concentrations were 0.34-0.39 µM. 
'Inhibitor concentrations were 0.42-0.Sl µM. 
•Inhibitor concentrations were 0.42--0.47 µM. 
"Inhibitor concentrations were 8.3-41 µM. 
linhibitor concentrations were 3.5-5.0 µM, r-t·PA = recombinant-tissue plasminogen activator. 
'Inhibition was not time dependent and the percentage was measured at 0.~5.0 µM. 
TABLE III 
Inhibition of Serine Proteases b;t 7-Substituted-4-chloro-3-isothiureidoalkoxyjsocoumarins•. 
!a1zi[I] {M-ls-ll 
Compounds PPEh HLF Chymotrypsind Cathepsin Gb 
PhCH2NHCONH-CiTPrOIC 9%' 250 13,430 so 
CH3CONH-CiTPrOIC mf 200 S,200 31 
PhCH2CONH-CiTPrOIC NI 130 260.~ 64 
PhNHCONH-CiTEtOIC 840 46,oooh 16,000 100 
5,730 
Boc-D-Phe-NH-CiTEtOIC 12%f 3,100 220 35 
L-Phe-NH-CiTEtOIC NI NI 8,400 53 
S-C6ff5(CH3)CHNHCONH-CiTEtOIC 21 o/.I 5,looh 260 35 
360 
R-C6ff5(CH3)CHNHCONH-CiTEtOIC 9o/.I 40%i 360 145 
"Inhibition rates were measured in O.lM Hepes, 0.05M NaCl, pH 7.5 buffer, 8-9% MeiSO and at 25• C. Substrates 
were Sue-Ala-Ala-Ala-Na (0.48 mM) for PPE; MeO-Suc-Ala-Ala-Pro-Val-NA (0.24 mM) for HLE; Suc-Val-Pro-
Pbe-NA (0.48 mM) for chymotrypsin and cathepsin G. 
binhibitor concentrations were 33-46 µM. 
'Inhibitor concentrations were 2.1-42 l'M. 
"inhibitor concentrations were 0.9-43 µM. 
fJ>ercentage of inhibition was obtained after 20 min incubation of enzyme with inhibitor. 
/No inhibition. 
•Second order of rate constant WIS obtained at equal molar concentrations of enzyme and inhibitor. 
"Inhibition WIS biphasic. 
ipercentage of inhibition wa.s obtained after S min incubation of enzyme with inhibitor. 
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17 
TABLE IV 
Effect of 7-Substituted-4-chloro-3-(2-isothiureidoethoxy) 
isocoumarins on PT and APTT in Pig Plasmaa. 
[I] PT APTT 
Compounds (µ.M) (sec) (sec) 
Control 0 18.6 17.7 
PhNHCONH-CiTEtOIC 16 28.5 >120 
32 58.3 
PhCH2NHCONH-CiTEtOIC 32 31.1 >120 
S-C6fis(CH3)CHNHCONH-CiTEtOIC 32 30.0 >120 
R-C6Hs(CH3)CHNHCONH-CiTEtOIC 32 26.2 >120 
QA vcrage of two trials 
TABLE V 
Hydrolysis Rates of 
7-Substituted-4-chloro-3-isothiurcidoalkoxyisocoumarinsa. 
Compounds lj (min) 
NH2-CiTPrOIC 90 
PhCH2NHCONH-CiTPrOIC 148 
PhNHCONH-CiTPrOIC 148 
CH3CONH-CiTPrOIC 68 
PhCH2CH2CONH-CiTPrOIC 66 
PhCH2CONH-CiTPrOIC 61 
PhNHCONH-CiTEtOIC 108 
"Half-life for the hydrolysis was measured in 0.IM Hepcs, O.OIM CaCl2. pH 7.S 
buffer, 8% Me2SO and at 2S' C. 
What is claimed is: 
1. A compound of the formula: 
0 
R~~ 
~z 
y 
or a pharmaceutically acceptable salt thereof, wherein 
5 
IO 
15 
20 
25 
35 
Z is selected form the group consisting of C 1-6 alkoxy 
with an amino group attached to the alkoxy group, 
C1-6 alkoxy with an isothiureido group attached to 40 
the alkoxy group, C1-6 alkoxy with a guanidino 
group attached to the alkoxy group, C1-6 alkoxy 
with an amidino group attached to the alkoxy 
group, Ct-6 alkyl_with an amino group attached to 
the alkyl group, C1-6 alkyl with an isothiureido 45 
50 
55 
60 
65 
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group attached to the alkyl group, C1-6 alkyl with 
an guanidino group attached to the alkyl group, 
C1-6 alkyl with an amidino group attached to the 
alkyl group, 
R is selected for the group consisting of O=C=N-, 
S==C=N-, AA-NH-, AA-AA-NH-, 
AA-0-, AA-AA-0-, M-NH-, 
M-AA-NH-, M-AA-AA-NH-, 
M-0-, M-AA-0-, or M-AA-AA-0-, 
wherein AA represents alanine, valine, leucine, iso-
leucine, methionine, phenylalanine, glucine, serine, 
threonine, cysteine, tyrosine, asparagine, gluta-
mine, aspartic acid, glutamic acid, lysine, arginine, 
beta-alanine, norleucine, norvaline, alpha-
aminobutyric acid, epsilon-aminocaproci acid, cit-
rulline, hydroxyproline, omithine or sarcosine, 
wherein M represents NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS-, 
X-NH-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CO-, X-0-CS-, 
wherein X represents C1-6 alkyl, C1-6 fluoroalkyl, 
C1-6 alkyl substituted with K, or C1-6 fluoroalkyl 
substituted with K, 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2,C1-6 alkoxy, C1.6filkylamine, C1-6 dialk-
ylamine, or C1-6 alkyl-0-CO-, 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
2. The compound of claim 1 wherein X represents 
phenyl, phenyl substituted with J, phenyl disubstituted 
with J, phenyl trisubstituted with J, naphthyl, naphthyl 
substituted with J, naphthyl disubstituted with J, or 
naphthyl trisubstituted with J, 
wherein J represents halogen, COOH, OH, CN, N02, 
NH2,C1-6 alkoxy, C1.6 alkyl, C1.6 alkylamine, C1-6 
dialkylamine, or C1-6 alkyl-0-CO-. 
3. The compound of claim 1 wherein X represents 
C1-6 alkyl with an attached phenyl group, or C1-6 alkyl 
with two attached phenyl groups. 
4. The compound of claim 1 wherein X represents 
C1-6 alkyl with an attached phenyl group substituted 
with J, or C1-6 alkyl with two attached phenyl groups 
substituted with J. 
• • • • • 
